NCT06701201
A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
Enrolling by Invitation
Not specifiedAges 18+ObservationalVerismo Therapeutics
~60 participants
Updated 2026-02-10 on ClinicalTrials.gov
What's tested:SynKIR-110SynKIR-310
At a glance
Recruiting sites
0 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To monitor the long-term safety of participants that have been infused with a SynKIR CAR T cell product
Measured over Up to 15 years from SynKIR CAR T cell product administration
+1 more outcome measured
Conditions
Where it's being run
6 sites across 6 statesColorado1
Georgia1
Kansas1
Pennsylvania1
Texas1
Wisconsin1
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- To monitor the long-term safety of participants that have been infused with a SynKIR CAR T cell productUp to 15 years from SynKIR CAR T cell product administration
Frequency and severity of delayed AEs considered related to SynKIR CAR T cell product
- To monitor the long-term safety of participants that have been infused with a SynKIR CAR cell productUp to 15 years from SynKIR CAR T cell product administration
Presence of RCL VSV-G DNA